Brasada Capital Management LP Sells 25,093 Shares of Danaher Corporation $DHR

Key Points

• Brasada Capital Management LP reduced its stake in Danaher Corporation by 38.1% in Q1, holding now 40,808 shares valued at approximately $8.37 million.
• Institutional investors own 79.05% of Danaher Corporation, with several hedge funds recently increasing their positions significantly.
• Danaher reported earnings per share of $1.80 for the last quarter, exceeding estimates, with revenue of $5.94 billion, up 3.4% year-over-year.

Brasada Capital Management LP lessened its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 38.1% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 40,808 shares of the conglomerate's stock after selling 25,093 shares during the period. Danaher accounts for 1.6% of Brasada Capital Management LP's holdings, making the stock its 21st biggest position. Brasada Capital Management LP's holdings in Danaher were worth $8,366,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the business. Coastal Bridge Advisors LLC raised its stake in Danaher by 4.8% in the 4th quarter. Coastal Bridge Advisors LLC now owns 1,099 shares of the conglomerate's stock valued at $252,000 after acquiring an additional 50 shares during the period. Hills Bank & Trust Co raised its stake in Danaher by 0.3% in the 1st quarter. Hills Bank & Trust Co now owns 18,015 shares of the conglomerate's stock valued at $3,693,000 after acquiring an additional 53 shares during the period. Sageworth Trust Co grew its holdings in Danaher by 2.3% in the 1st quarter. Sageworth Trust Co now owns 2,404 shares of the conglomerate's stock valued at $493,000 after buying an additional 54 shares in the last quarter. 1834 Investment Advisors Co. grew its holdings in Danaher by 3.3% in the 1st quarter. 1834 Investment Advisors Co. now owns 1,666 shares of the conglomerate's stock valued at $342,000 after buying an additional 54 shares in the last quarter. Finally, Rakuten Securities Inc. grew its holdings in Danaher by 33.3% in the 1st quarter. Rakuten Securities Inc. now owns 224 shares of the conglomerate's stock valued at $46,000 after buying an additional 56 shares in the last quarter. Institutional investors own 79.05% of the company's stock.

Insider Buying and Selling

In other news, Director Teri List sold 2,778 shares of the firm's stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 11.10% of the company's stock.

Danaher Trading Down 2.2%

Danaher stock traded down $4.39 during trading hours on Wednesday, hitting $199.40. The stock had a trading volume of 3,468,205 shares, compared to its average volume of 4,157,149. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock has a market cap of $142.78 billion, a price-to-earnings ratio of 42.43, a P/E/G ratio of 2.87 and a beta of 0.75. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90. The business's 50 day simple moving average is $201.97 and its 200-day simple moving average is $199.49.

Danaher (NYSE:DHR - Get Free Report) last posted its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 EPS for the quarter, beating the consensus estimate of $1.64 by $0.16. The firm had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business's quarterly revenue was up 3.4% on a year-over-year basis. During the same period last year, the company earned $1.72 earnings per share. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. On average, equities analysts predict that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on DHR shares. Evercore ISI decreased their price objective on Danaher from $230.00 to $226.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Robert W. Baird upped their price objective on Danaher from $225.00 to $226.00 and gave the company an "outperform" rating in a report on Friday, July 18th. Scotiabank raised Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 price objective on the stock in a report on Friday, July 11th. Wells Fargo & Company reduced their target price on Danaher from $210.00 to $205.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 23rd. Finally, UBS Group reduced their target price on Danaher from $240.00 to $225.00 and set a "buy" rating on the stock in a report on Wednesday, July 23rd. Seventeen research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $246.35.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.